Hey Everyone!
I'm a new poster to the ANP Hot Copper however I've been invested since April this year and have been aware of ANP for longer than that.
I thought I'd share some brief research I did today regarding the news that dropped for ATL1102's role in LTBP4 modulation.
I've tried to cite my data/sources where applicable - please let me know any limitations/improvements to this that you find or add any on information you've come across.
Looking forward to any further insights/commentary you can provide
- I will be using this as a summary document for any friends or colleagues that I discuss ANP with (note that the full document provides detail of the ANP pathway, key value drivers and ATL1102 mechanism of action prior to today's news)
ATL1102 modulation of LTBP4
ANP has discovered that ATL1102 has been found tomodulate the levels of latent TGF binding protein 4 (LTBP4) in the populationin non-ambulant boys within their DMD phase 2 clinical trial.
Link:
https://www.antisense.com.au/wp-content/uploads/2021/09/ASX-22_20-September_ATL1102-World-Muscle-Society-poster-presentation_V1.1.pdf
Additional study: https://pubmed.ncbi.nlm.nih.gov/21468687/
ATL1102 Presence + Indications in other diseases
Breast Cancer ( Estimated 2027 Market Size: ~ 55B)
(https://www.fortunebusinessinsights.com/industry-reports/breast-cancer-therapeutics-market-100163)
Info:
(https://pubmed.ncbi.nlm.nih.gov/21505857/)
Additional study:https://pubmed.ncbi.nlm.nih.gov/21468687/
-VersicanG1 and G3 domains are upregulated and latent transforming growth factor-β binding protein-4 is downregulated in breastcancer stroma
-Conclusion:the stromal alterations of Versican and LTBP-4 might influence thecarcinogenesis and progression of breast tumor cells and modulate theirbiological phenotypes
-Note:the full text article was unavailable however the conclusion and title suggeststhat down regulation of LTBP4 may contribute/be a result of breast cancerprogression, i.e. upregulation or modulation of this protein may havetherapeutic outcomes
Scleroderma (Estimated 2027 Market Size: ~ 3.8B)
(https://www.acumenresearchandconsulting.com/scleroderma-therapeutics-market)
Info:
(https://www.nature.com/articles/labinvest201720)
-Humanmodels have shown that LTBP4 modulates TGF-Beta secretion and collagenformation (excess collagen formation is implicated in scleroderma)
-LTBP4may also be implicated in other fibrotic related diseases (pulmonaryfibrosis – idiopathic pulmonary fibrosis market share is estimated ~8B,link:https://www.ihealthcareanalyst.com/global-idiopathic-pulmonary-fibrosis-treatment-market/
-Conclusion:LTBP4 may participate fibrotic component of scleroderma through collagenproduction
-Take-aways:LTBP4 seems to be implicated in a number of fibrotic associat
ed diseases
Esophageal and Gastrointestinal Cancer (Estimated 2027Market Size: ~9B)
(https://www.futurewiseresearch.com/healthcare-market-research/Esophageal-Cancer-Drugs/11288)
(https://www.wboc.com/story/44230148/stomach-cancer-treatment-market-2021-2026-size-share-growth-trends#:~:text=The%20World%20Health%20Organization%20(WHO,15.3%25%20during%20the%20forecast%20period.)
Info:
(https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0065614)
-“Analysisof patient tissues of various adenocarcinomas of the gastrointestinal tractrevealed significant downregulation of LTBP4 in comparison to normal tissues ofthe same organ. In detail, adenocarcinomas of esophagus showed 37%, of stomach17%, of pancreas 9%, of small intestine 4% and of colon 22% LTBP4 expression”
-Conclusion:if ATL1102 can upregulate LTPB4 then it can potentially work as a therapeuticor prophylactic in these cancers (prophylactic potential comes from thehistorical LTBP4 knockdown being a precursor to tumorogenesis)
Glioblastoma (Estimated 2027 Market Size: ~ 4.2B)
(https://au.finance.yahoo.com/news/glioblastoma-multiforme-treatment-market-size-080400829.html#:~:text=The%20global%20glioblastoma%20multiforme%20treatment,novel%20therapy%20and%20combination%20therapy.)
Info:
-HighLTBP4 levels are associated with poor prognoses in glioblastoma (GBM) patients
-LTBP4moderates TGF-Beta expression which seems to form the basis of geneexpression/carcinoma cell proliferation in GBM (somewhat similar inferencesfrom the other cancers described in brief above)
Abdominal AorticAneurysm (Estimated 2027 Market Size: ~ 4.71B)
(https://www.prnewswire.com/news-releases/aortic-aneurysm-market-size-worth-4-71-billion-by-2026--cagr-8-6-grand-view-research-inc-300905665.html)
Info:
-The LTBP4 gene may be linked to Abdominal AorticAneurysm progression
Conclusion:
-LTBP4 downregulation, upregulation and mutation ispresent with a number of different cancers and disease states
-This provides potential additional therapeutic scopefor ATL1102, depending on what the capacity of the drug is to ‘modulate’ LTBP4
-IF ATL1102can down regulate LTBP4 it will have potential applications in GBM, BC(Market Size ~ 59B)
-IF ATL1102can up regulate LTBp4 it will have potential applications in colorectal cancers(Market Size ~ 9B)
Competitor Drugs thatregulate/modulate LTBP4/TGF-Beta expression/levels
So far as I can see, thereare no patented drugs or references to any researched compounds that modulateLTBP4.
(20min delay)